CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificate is attached herewith22-03-2024
22-03-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificate is attached herewith07-03-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificates are attached herewith27-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificate is attached herewith19-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The link for the transcript of the earnings call w.r.t to the financial performance of the company for quarter and 9 months ended 31-12-2023 is enclosed.16-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement w.r.t Q3 (2023-24) financial results is attached10-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Website link for Audio recordings of investor meeting/ Investor call is enclosed09-02-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Caplin Point Laboratories Ltd.
Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23. Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23. Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23. Gross Margin%: 56.3%, increased from 55.9% in Q3FY23. EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23. EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23. PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23. PBT Margin%: 32.1%, increased from 28.9% in Q3FY23. PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23. PAT Margin%: 26.5%, increased from 25.2% in Q3FY23. Consolidated 9MFY24: Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23. Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23. Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23. Gross Margin%: 57.1%, increased from 54.8% in 9MFY23. EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23. EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23. PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23. PBT Margin%: 32.4%, increased from 29.2% in 9MFY23. PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23. PAT Margin%: 26.4%, increased from 24.6% in 9MFY23. Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows". Result PDF09-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Outcome for Financial Results For The Quarter Ended December 31, 2023
Financial Results along with the Limited Review Report, Press Release and Investor PPT for the QE December 31, 2023 is enclosed09-02-2024
CAPLIN POINT LABORATORIES LTD. - 524742 - Financial Results For The Quarter Ended December 31, 2023
Financial Results along with the Limited Review Report, Press Release and Investor PPT for the quarter ended December 31, 2023 is enclosed09-02-2024